title: SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.
abstract: OBJECTIVE
  To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments.
  
  
  RESULTS
  Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03).
  
  
  CONCLUSIONS
  Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.
authors.affiliation: Retina Consultants of Houston, the Methodist Hospital, Houston, TX 77030, USA. ccwmd@houstonretina.com
authors.forename: Charles C
authors.initials: CC
authors.lastname: Wykoff
authors.forename: David M
authors.initials: DM
authors.lastname: Brown
authors.forename: Eric
authors.initials: E
authors.lastname: Chen
authors.forename: James C
authors.initials: JC
authors.lastname: Major
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Croft
authors.forename: Angeline
authors.initials: A
authors.lastname: Mariani
authors.forename: Tien P
authors.initials: TP
authors.lastname: Wong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D005451:Fluorescein Angiography; D049671:History, 18th Century; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011446:Prospective Studies; D000069579:Ranibizumab; D012029:Refraction, Ocular; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab